NovaBridge Taps Emmett Cunningham with 25-Year Biotech Track Record as Vice Chairman
NovaBridge appointed Emmett T. Cunningham Jr., MD, PhD, MPH as Vice Chairman of the Board and member of its Research and Development Committee to accelerate its hub-and-spoke biotech platform. Cunningham brings 25 years of leadership at Blackstone and Clarus Ventures; he co-founded Visara to bolster development of givastomig and VIS-101.
1. Board Appointment and Committee Role
NovaBridge appointed Emmett T. Cunningham Jr., MD, PhD, MPH, as Vice Chairman of the Board and named him to the Research and Development Committee to guide strategic decisions and oversight of clinical asset advancement.
2. Cunningham’s Biotech Leadership Background
Dr. Cunningham has 25 years of biopharma leadership, including roles as Senior Managing Director at Blackstone, Managing Director at Clarus Ventures, early‐stage development leadership at Pfizer and Eyetech, and co‐founder of Visara; he has authored over 450 publications in ophthalmology.
3. Strategic Impact on NovaBridge Pipeline
Cunningham’s appointment supports NovaBridge’s hub-and-spoke model by accelerating development of givastomig, a Claudin 18.2 × 4-1BB bispecific antibody in Phase 2, and VIS-101, a VEGF-A/ANG2 bifunctional biologic in Phase 2a, aiming to drive durable clinical progress and shareholder value.